FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Update

FibroBiologics Inc. (NASDAQ:FBLG) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 851,743 shares, an increase of 128.4% from the January 15th total of 372,855 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average trading volume of 689,374 shares, the short-interest ratio is presently 1.2 days. Based on an average trading volume of 689,374 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the company’s shares are sold short.

FibroBiologics Stock Up 2.0%

FBLG traded up $0.01 during midday trading on Friday, hitting $0.25. 457,242 shares of the company traded hands, compared to its average volume of 1,484,438. The company’s 50-day moving average is $0.29 and its 200 day moving average is $0.42. The firm has a market capitalization of $16.70 million, a PE ratio of -0.52 and a beta of -0.60. FibroBiologics has a 52 week low of $0.22 and a 52 week high of $1.53.

Insider Transactions at FibroBiologics

In related news, General Counsel Ruben A. Garcia bought 140,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $0.34 per share, with a total value of $47,600.00. Following the transaction, the general counsel owned 140,000 shares in the company, valued at approximately $47,600. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 13.00% of the company’s stock.

Institutional Trading of FibroBiologics

A number of hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new position in shares of FibroBiologics during the 2nd quarter worth $37,000. Cascade Financial Partners LLC raised its holdings in FibroBiologics by 11.7% in the 2nd quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock worth $181,000 after purchasing an additional 30,500 shares during the period. Yorkville Advisors Global LP purchased a new position in FibroBiologics during the third quarter valued at $278,000. AMG National Trust Bank bought a new stake in FibroBiologics during the fourth quarter valued at about $31,000. Finally, Jane Street Group LLC bought a new stake in FibroBiologics during the fourth quarter valued at about $34,000.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FBLG. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of FibroBiologics in a research report on Tuesday, January 6th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of FibroBiologics in a research note on Friday, January 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, FibroBiologics presently has a consensus rating of “Hold” and an average price target of $10.00.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.